Myoblasts treated with AF showed lower levels of Tgfbr1 and Tgfbr2 transcripts compared to those treated with coACCM (Figure 4A), suggesting that AF can reduce TGF-ß activation. This evidence concerns the gene TGFBR2 and atrial fibrillation.